A Polyclonal Antibody against a Burkholderia cenocepacia OmpA-like Protein Strongly Impairs Pseudomonas aeruginosa and B. multivorans Virulence
暂无分享,去创建一个
[1] S. Sousa,et al. Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections , 2022, Vaccines.
[2] A. Garratt,et al. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[3] S. Sousa,et al. A Polyclonal Antibody Raised against the Burkholderia cenocepacia OmpA-like Protein BCAL2645 Impairs the Bacterium Adhesion and Invasion of Human Epithelial Cells In Vitro , 2021, Biomedicines.
[4] S. Sousa,et al. Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections , 2021, Vaccines.
[5] Andreia I. Pimenta,et al. Burkholderia cenocepacia BCAM2418‐induced antibody inhibits bacterial adhesion, confers protection to infection and enables identification of host glycans as adhesin targets , 2021, Cellular microbiology.
[6] S. Sousa,et al. Characterization of the Burkholderia cenocepacia J2315 Surface-Exposed Immunoproteome , 2020, Vaccines.
[7] E. Torrents,et al. Differential adaptability between reference strains and clinical isolates of Pseudomonas aeruginosa into the lung epithelium intracellular lifestyle , 2020, Virulence.
[8] C. Sen,et al. Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption , 2017, Scientific Reports.
[9] Evan Bolton,et al. Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..
[10] E. Giralt,et al. Combating virulence of Gram-negative bacilli by OmpA inhibition , 2017, Scientific Reports.
[11] L. Chiarelli,et al. Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches , 2017, Front. Microbiol..
[12] Bjoern Peters,et al. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes , 2017, Nucleic Acids Res..
[13] V. Cooper,et al. Long-Term Evolution of Burkholderia multivorans during a Chronic Cystic Fibrosis Infection Reveals Shifting Forces of Selection , 2016, mSystems.
[14] G. O’Toole,et al. Cystic Fibrosis Lung Infections: Polymicrobial, Complex, and Hard to Treat , 2015, PLoS pathogens.
[15] Raymond Lo,et al. Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database , 2015, Nucleic Acids Res..
[16] M. Valvano. Intracellular survival of Burkholderia cepacia complex in phagocytic cells. , 2015, Canadian journal of microbiology.
[17] S. McClean,et al. The Tyrosine Kinase BceF and the Phosphotyrosine Phosphatase BceD of Burkholderia contaminans Are Required for Efficient Invasion and Epithelial Disruption of a Cystic Fibrosis Lung Epithelial Cell Line , 2014, Infection and Immunity.
[18] P. Gilligan,et al. Localization of Burkholderia cepacia Complex Bacteria in Cystic Fibrosis Lungs and Interactions with Pseudomonas aeruginosa in Hypoxic Mucus , 2014, Infection and Immunity.
[19] E. Hoffman,et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis , 2014, Science.
[20] A. Fialho,et al. Characterization of BCAM0224, a Multifunctional Trimeric Autotransporter from the Human Pathogen Burkholderia cenocepacia , 2014, Journal of bacteriology.
[21] J. Klockgether,et al. Developing an international Pseudomonas aeruginosa reference panel , 2013, MicrobiologyOpen.
[22] C. Heiner,et al. Draft Genome Sequences of Burkholderia cenocepacia ET12 Lineage Strains K56-2 and BC7 , 2013, Genome Announcements.
[23] A. Confer,et al. The OmpA family of proteins: roles in bacterial pathogenesis and immunity. , 2013, Veterinary microbiology.
[24] Susan Murray,et al. Decade-long bacterial community dynamics in cystic fibrosis airways , 2012, Proceedings of the National Academy of Sciences.
[25] S. Molin,et al. Phenotypes of Non-Attached Pseudomonas aeruginosa Aggregates Resemble Surface Attached Biofilm , 2011, PloS one.
[26] N. Høiby,et al. Pseudomonas aeruginosa biofilms in cystic fibrosis. , 2010, Future microbiology.
[27] S. McClean,et al. Invasion of Burkholderia cepacia complex isolates into lung epithelial cells involves glycolipid receptors. , 2010, Microbial pathogenesis.
[28] P. Dřevínek,et al. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[29] S. Sousa,et al. Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species , 2010, Applied Microbiology and Biotechnology.
[30] H. Nelis,et al. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. , 2009, The Journal of antimicrobial chemotherapy.
[31] N. Høiby,et al. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[32] Raymond Lo,et al. The Burkholderia Genome Database: facilitating flexible queries and comparative analyses , 2008, Bioinform..
[33] Jonathan J. Dennis,et al. Development of Galleria mellonella as an Alternative Infection Model for the Burkholderia cepacia Complex , 2008, Infection and Immunity.
[34] Stephen G. J. Smith,et al. A molecular Swiss army knife: OmpA structure, function and expression. , 2007, FEMS microbiology letters.
[35] L. Tamm,et al. Electrostatic couplings in OmpA ion-channel gating suggest a mechanism for pore opening , 2006, Nature chemical biology.
[36] A. Torres,et al. Outer Membrane Protein A of Escherichia coli O157:H7 Stimulates Dendritic Cell Activation , 2006, Infection and Immunity.
[37] Amos Bairoch,et al. The PROSITE database , 2005, Nucleic Acids Res..
[38] Joanna B. Goldberg,et al. The multifarious, multireplicon Burkholderia cepacia complex , 2005, Nature Reviews Microbiology.
[39] S. Sousa,et al. Studies on the Involvement of the Exopolysaccharide Produced by Cystic Fibrosis-Associated Isolates of the Burkholderia cepacia Complex in Biofilm Formation and in Persistence of Respiratory Infections , 2004, Journal of Clinical Microbiology.
[40] P. Vandamme,et al. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. , 2002, The Journal of antimicrobial chemotherapy.
[41] G. Novelli,et al. Isolation of CF cell lines corrected at ΔF508-CFTR locus by SFHR-mediated targeting , 2002, Gene Therapy.
[42] Gerald B. Pier,et al. Lung Infections Associated with Cystic Fibrosis , 2002, Clinical Microbiology Reviews.
[43] J. Lyczak,et al. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. , 2000, Microbes and infection.
[44] C. Mohr,et al. Invasion and Intracellular Survival ofBurkholderia cepacia , 2000, Infection and Immunity.
[45] J. Engel,et al. Pili Binding to Asialo-GM1 on Epithelial Cells Can Mediate Cytotoxicity or Bacterial Internalization byPseudomonas aeruginosa , 1999, Infection and Immunity.
[46] J. Costerton,et al. Bacterial biofilms: a common cause of persistent infections. , 1999, Science.
[47] C. Schmid,et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. , 1998, The New England journal of medicine.
[48] G. Pier,et al. Pseudomonas aeruginosa invasion of and multiplication within corneal epithelial cells in vitro , 1995, Infection and immunity.
[49] M. Corey,et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. , 1984, The Journal of pediatrics.
[50] OUP accepted manuscript , 2022, Nucleic Acids Research.
[51] M. Amaral,et al. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. , 2015, Pharmacology & therapeutics.
[52] J. Bhatt,et al. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. , 2014, The Cochrane database of systematic reviews.